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Background: There are conflicted results with regards the impact of an elevated circulated level of asymmetric dimethylarginine (ADMA) on the 
mortality of patients with acute decompensated heart failure and reduced left ventricular ejection fraction. The aim of this study was to prospectively 
investigate this issue.
Methods:  A total of 651 consecutive pts who were hospitalized due to acute decompensated heart failure and reduced left ventricular ejection 
fraction (LVEF<=35%) were studied. The cohort was divided into 4 groups according to the quartiles of circulated level of ADMA upon presentation. 
The incidence of 1-year mortality was the prespecified study endpoint.
Results:  There were no significant baseline diferences among the 4 groups. By 1-year the primary endpoint was reached by 36.4% of pts. There was 
a gradual increased risk of the primary end point with increasing of ADMA quartiles (24.5%, 31.4%, 41.7% and 48.1% for the first, second, third and 
fourth quartile respectively; p for trend<0.001) (Figure). By multivariate Cox regression analysis an elevated circulated level of ADMA was among the 
stronger predictors of the primary end point (RR=2.5; p<0.001).
Conclusions:  According to the present study an elevated circulated level of ADMA is a strong independent predictor of long-term mortality in pts 
with acute decompensated heart failure and reduced left ventricular ejection fraction. ADMA levels upon presentation may confer enhanced risk 
stratification in this setting. 
